Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
Published 4 August 2009, doi:10.1136/bmj.b3146
Cite this as: BMJ 2009;339:b3146
| The first 150 words of the full text of this article appear below. |
The exceptional heat wave in 2003 led to excess mortality, particularly in elderly people1—in France about 14 800 deaths, mainly among people over 70.2
We evaluated adverse drug reactions reported to the French network of pharmacovigilance centres during the summer of 2003 in patients older than 70.3 Sixty eight reactions were serious. They were mainly metabolic (dehydration, hydroelectrolytic disorders) and neuropsychiatric (confusion, disorientation, coma). The drugs frequently implicated were diuretics, angiotensin converting enzyme inhibitors, serotoninergic antidepressants, proton pump inhibitors, digoxin, benzodiazepines, and sartans.
Pharmacoepidemiological studies are needed to help doctors to reconsider patients treatments during a heat wave and inform patients and families of the drug related dangers. In the summer of 2007 the French drug agency instigated a multicentre case-control pilot study of drug exposure in patients older than 65 admitted for hyperthermia or dehydration.4 Although there was no heat wave that year, similar methods can be used
Agnès Sommet, pharmacoepidemiologist1, Anne Castot, head2, Jean-Louis Montastruc, professor and head1
1 Department of Clinical Pharmacology, Unité de Pharmacoépidémiologie EA 3696, Université de Toulouse, 31000-Toulouse, France, 2 Département de la Surveillance du Risque, du Bon Usage et de lInformation sur les Médicaments, Agence Française de Sécurité Sanitaire des Produits de Santé, 93285-Saint-Denis Cedex, France
sommet@cict.fr